Well, finally the criticism has forced
the American Association of Clinical Endocrinologists (AACE) into
action. They have now issued a new type 2 diabetes algorithms
consensus statement to accompany the original algorithms. This
consensus statement is 48 pages in length and is available
for free download. Yes, again, it is in the
PDF format and the original 8 pages of the diabetes algorithms are
turned on their side to make them more difficult to read.
Now I must ask, did the criticism
finally bring them to their senses? It may have, plus the blogger
gnats may have become pesky enough. I think that Dr. Anne Peters and
Dr. Jerry Avorn articles convinced them
to do more. What is important is the disclosure of the ties to Big
Pharma including for Dr. Alan J Garber, who has some rather
substantial conflicts of interest. These disclosures start on page
29 and while are not surprising, do show how tied to the drug
companies most of the people are. This is just one more reason to be
cautious about relying on the AACE diabetes algorithms.
What I find upsetting is the continued
reference to the benefits of weight loss surgery or bariatric surgery
as being the recommendation of preference. We know that this is not
the cure-all claimed and many people are not able to maintain the
strict diet required for bariatric surgery to be successful in the
long term. The references chosen of course do not include the
discussion in this Medical News Today article which emphasizes following the
diet recommended for those that have bariatric surgery and receiving
many if not most of the benefits.
I find the prediabetes section almost
insulting as they say the primary goal of prediabetes management is
weight loss as if everyone with prediabetes is overweight. I have
met many patients with prediabetes that are not overweight. They
continue that, when indicated, bariatric surgery can also be highly
effective in preventing progression to diabetes. At least they felt
obligated to say, weight loss may not directly address the
pathogenesis of declining beta-cell function.
I am very surprised that no mention is
made of medications being used “off label” because at present the
FDA does not list any approved oral diabetes medications for
prediabetes. Because metformin and acarbose are generic and
relatively inexpensive to purchase, I can accept this. However, I
think it would be wise for the drug manufacturers that the American
Diabetes Association (ADA) and the AACE support with their dogma to
have these approved. There are several other medications promoted in
the Consensus that also should be on the approved list of drugs
before they are used “off label.” These currently have FDA
warnings, but AACE does not want the patient to know of them.
The AACE Diabetes Algorithms consensus
statement is consistent in their promotion of weight loss and
bariatric surgery as often the best option. They are also consistent
in making readers aware of preventing hypoglycemia as a priority.
As I have time to study the consensus
statement further, I will blog about it and I am hoping to see other
professionals making statements about the consensus statement.